Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family

Author(s): Ali Farhang Boroujeni and Zeynep Ates-Alagoz*

Volume 25, Issue 3, 2025

Published on: 20 September, 2024

Page: [164 - 178] Pages: 15

DOI: 10.2174/0118715206320224240910054728

Price: $65

Open Access Journals Promotions 2
Abstract

Currently, breast cancer is the most common cancer type, accounting for 1 in every 4 cancer cases. Leading both in mortality and incidence, breast cancer causes 1 in 4 cancer deaths. To decrease the burden of breast cancer, novel therapeutic agents which target the key hallmarks of cancer, are being explored. The Bcl-2 family of proteins has a crucial role in governing cell death, making them an attractive target for cancer therapy. As cancer chemotherapies lead to oncogenic stress, cancer cells upregulate the Bcl-2 family to overcome apoptosis, leading to failure of treatment. To fix this issue, Bcl-2 family inhibitors, which can cause cell death, have been introduced as novel therapeutic agents. Members of this group have shown promising results in in-vitro studies, and some are currently in clinical trials. In this review, we will investigate Bcl-2 family inhibitors, which are already in trials as monotherapy or combination therapy for breast cancer, and we will also highlight the result of in vitro studies of novel Bcl-2 family inhibitors on breast cancer cells. The findings of these studies have yielded encouraging outcomes regarding the identification of novel Bcl-2 family inhibitors. These compounds hold significant potential as efficacious agents for employment in both monotherapy and combination therapy settings.

Keywords: Bcl-2 family inhibitors, Bcl-xL, Mcl-1, Bcl-2, synthetic scaffolds, breast cancer.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy